BioVie Inc Ordinary Shares - Class A BIVI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
BioVie Selected for Late-Breaking Oral Presentation of Bezisterim Long COVID Data at the 4th Long COVID International Conference 2026
-
From Global Private Credit to Programmable Securities: New to The Street Show #778 Premieres Tonight on Bloomberg Television
-
BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH’s RECOVER-TLC Third Annual Workshop
-
From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television
-
BioVie Presents Data on Bezisterim in Parkinson’s Disease at the 2026 American Neurological Association Annual Meeting
-
BioVie Presents Data on Bezisterim in Long COVID at the 2026 American Neurological Association Annual Meeting
-
Powering the AI Economy: New to The Street Show #776 Premieres Tonight on Bloomberg Television
-
BioVie to Present New Bezisterim Findings in Parkinson’s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting
Trading Information
- Previous Close Price
- $1.43
- Day Range
- $1.36–1.42
- 52-Week Range
- $0.84–3.79
- Bid/Ask
- $0.96 / $1.70
- Shares Outstanding
- 8.68M
- Market Cap
- $11.90M
- Volume/Avg
- 120,477 / 4M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 13
- Website
- https://www.bioviepharma.com
Valuation
|
Metric
|
BIVI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.05 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BIVI
|
|---|---|
Quick Ratio | 2.93 |
Current Ratio | 3.59 |
Interest Coverage | −1,265.39 |
Quick Ratio
BIVI
Profitability
|
Metric
|
BIVI
|
|---|---|
Return on Assets (Normalized) | −93.52% |
Return on Equity (Normalized) | −107.77% |
Return on Invested Capital (Normalized) | −109.10% |
Return on Assets
BIVI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|dxX^K#g | LOCK|#dGD! | $142B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|BC>MjQ< | LOCK|@X@^ | $96B | |||
| Moderna Inc
MRNA
| LOCK|#C?j?D | LOCK|V# | $89B | |||
| argenx SE ADR
ARGX
| LOCK|FZ>$cF | LOCK|$< | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|R#V%&l | LOCK|w@l | $43B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|tdt@TMn | LOCK|!>>M | $30B | |||
| Incyte Corp
INCY
| LOCK|@RSXqx | LOCK|$&Y | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|lyrt$L@ | LOCK|W# | $22B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|!hYQ$&F | LOCK|gv@G | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|<@BM<G | LOCK|#! | $15B |
United States